Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Clinical Study Evaluating the Safety and Efficacy of GT801 Injection in Adult Patients With Relapsed/Refractory CD19-positive B-cell Hematologic Malignancies and Autoimmune Hemolytic Anemia

NCT07205315 is registered in ClinicalTrials.gov with Grit Biotechnology as lead sponsor.

NCT NCT07205315
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07205315 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Clinical Study Evaluating the Safety and Efficacy of GT801 Injection in Adult Patients With Relapsed/Refractory CD19-positive B-cell Hematologic Malignancies and Autoimmune Hemolytic Anemia
Lead sponsor
Grit Biotechnology
Phase
Phase 1
Overall status
Recruiting
Start date
September 26, 2025
Completion date
August 31, 2028
Enrollment
28 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

autoimmune hemolytic anemia (aiha), b-cell acute lymphoblastic leukemia (b-all), b-cell non-hodgkin's lymphoma (b-nhl), chronic lymphocytic leukemia (cll)